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Abstract 30 
Introduction: In addition to the well-known cartilage extracellular matrix-related expression of Sox9, 31 
we demonstrated that chondrogenic differentiation of progenitor cells is driven by a sharply defined 32 
bi-phasic expression of Sox9: an immediate early and a late (extracellular matrix associated) phase 33 
expression. In this study we aimed to determine what biological processes are driven by Sox9 during 34 
this early phase of chondrogenic differentiation.  35 
Materials: Sox9 expression in ATDC5 cells was knocked-down by siRNA transfection at the day 36 
before chondrogenic differentiation or at day 6 of differentiation. Samples were harvested at 2 hours, 37 
and 7 days of differentiation. The transcriptomes (RNA-seq approach) and proteomes (Label-free 38 
proteomics approach) were compared using pathway and network analyses. Total protein translational 39 
capacity was evaluated with the SuNSET assay, active ribosomes with polysome profiling and 40 
ribosome modus with bicistronic reporter assays.  41 
Results: Early Sox9 knockdown severely inhibited chondrogenic differentiation weeks later. Sox9 42 
expression during the immediate early phase of ATDC5 chondrogenic differentiation regulated the 43 
expression of ribosome biogenesis factors and ribosomal protein subunits. This was accompanied by 44 
decreased translational capacity following Sox9 knockdown, and this correlated to lower amounts of 45 
active mono- and polysomes. Moreover, cap- versus IRES-mediated translation was altered by Sox9 46 
knockdown. Sox9 overexpression was able to induce reciprocal effects to the Sox9 knockdown. 47 
Conclusion: Here we identified an essential new function for Sox9 during early chondrogenic 48 
differentiation. A role for Sox9 in regulation of ribosome amount, activity and/or composition may be 49 
crucial in preparation for the demanding proliferative phase and subsequent cartilage extracellular 50 
matrix-production of chondroprogenitors in the growth plate in vivo.   51 




Chondrogenesis, or chondrogenic differentiation, is the differentiation path of progenitor cells via early 53 
mesenchymal condensation into chondrocytes that synthesize a cartilaginous extracellular matrix 54 
(ECM) (1-3). Aside from formation of articular cartilage and its maintenance, skeletal development 55 
also depends on chondrogenic differentiation. Development of the long bones of the mammalian 56 
skeleton depends on the activity of growth plates; cartilaginous entities at the ends of developing bones 57 
in which chondrocytes differentiate from progenitor cells (1-3). In contrast to articular chondrocytes, 58 
differentiating growth plate chondrocytes are predestined to undergo hypertrophic differentiation and 59 
apoptosis. The remaining cartilaginous matrix is subsequently remodelled by osteoclastic/osteocytic 60 
activity, resulting in de novo synthesized bone tissue (1-3). In vivo, chondrogenic differentiation is 61 
almost exclusively initiated from local mesenchymal progenitor cells that reside in the cartilaginous 62 
tissue (growth plate resting zone (4), articular cartilage superficial layer(5)) or in surrounding fibrous 63 
tissues (e.g. periosteum (6, 7)). However, in vitro chondrogenic differentiation has been reported from 64 
various primary (mesenchymal) progenitor cell sources including synovial membrane/fluid, bone 65 
marrow, adipose tissue, fibroblasts, and induced pluripotent stem cells (8-10). In addition to high 66 
amounts of oligosaccharides (mostly hyaluronic acid, heparan sulphate, chondroitin sulfate), important 67 
cartilage ECM proteins are type II collagen (Col2a1) and aggrecan (Acan)(2, 11, 12).  68 
The master regulator of chondrogenic differentiation is the transcription factor SRY (sex determining 69 
region Y)-box 9 (Sox9). Mutations in SOX9 were originally identified as the cause for campomelic 70 
dysplasia (13, 14), a severe skeletal dysplasia associated with XY sex reversal and disproportionally 71 
short stature, as well as general lack of cartilaginous tissue formation. SOX9 was found to be essential 72 
for murine early chondrogenic lineage determination (15). Upon nuclear translocation (16, 17), Sox9 73 
binds as a homodimer to its consensus DNA recognition sequence (A/T)(A/T)CAA(A/T)G(18), which 74 
includes the highly conserved AACAAT motif recognized by the HMG-box domain shared amongst 75 
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Sox and Sry protein family members. In chondrogenic differentiation Sox9 drives the transcription of, 76 
and cooperates with L-Sox5 and Sox6 for efficient transcription of the COL2A1 and ACAN genes (15, 77 
19-22). Other cartilage ECM genes have also been demonstrated as under transcriptional control of 78 
SOX9; including COL9A1 (23), COL27A1 (24), and MATN1 (25, 26). Besides L-Sox5 and Sox6, 79 
another important factor for Sox9-mediated transcription is Smad3. Smad3 modulates the interaction 80 
between Sox9 and CBP (CREB-binding protein)/p300 (27), thereby possibly explaining the pro-81 
chondrogenic effect of bone morphogenetic proteins (BMPs) and transforming growth factor beta 82 
(TGFβs) on chondrogenic differentiation (28, 29). 83 
During chondrogenic differentiation of progenitor cells in vitro, induction of Sox9 expression is 84 
biphasic (30). In the first hours after initiation of chondrogenic differentiation Sox9 expression is 85 
transiently induced (immediate early Sox9 induction), together with the other members of the “Sox-86 
trio”. Sox9 expression increases a second time, in parallel with the synthesis of cartilage ECM 87 
molecules (late Sox9 induction). Previously, we demonstrated that this immediate early Sox9 88 
expression is in part regulated by the immediate early response gene 1 (Egr1) (31) as well as by 89 
NFB/p65 (30). Similar expression patterns were also found in growth plate sections (30). The function 90 
of the early Sox9 induction itself remains elusive. In the present work we therefore determined the 91 
transcriptomic and proteomic consequences of the abrogation of early Sox9 expression during ATDC5 92 
chondrogenic differentiation, and uncovered the biological processes that are driven by Sox9 during 93 
the early phase of chondrogenic differentiation.   94 
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Materials and methods 95 
 96 
ATDC5 cell culture 97 
ATDC5 cells (RIKEN BRC, Japan, STR profiled)(32) were cultured in a humidified atmosphere at 98 
37°C and 5% CO2 in culture media consisting of Dulbecco’s Modified Eagle Medium (DMEM)/F12 99 
(Life Technologies, Waltham, Massachusetts, USA), 5% fetal calf serum (Life Technologies), 1% 100 
antibiotic/antimycotic (Life Technologies) and 1% non-essential amino acids (NEAA)(Life 101 
Technologies). Chondrogenic differentiation was induced by plating the cells in triplicates at 6400 102 
cells/cm2, or 20,000 cells/cm2 in transfection experiments, and the addition to culture media of 103 
differentiation supplements 10 μg/ml insulin (Sigma-Aldrich, St. Louis, Missouri, United States), 10 104 
μg/ml transferrin (Roche, Basel, Switzerland), and 30 nM sodium selenite (Sigma–Aldrich). Media 105 
was refreshed every two days.  106 
 107 
Sox9 loss and gain of function 108 
A small interfering RNA (siRNA) duplex for Sox9 (“Sox9 RNAi”) (sense: 5’-109 
GACUCACAUCUCUCCUAAUTT-3’, anti-sense: 5’-AUUAGGAGAGAUGUGAGUCTT-3’) and a 110 
scrambled siRNA duplex (“Control RNAi”, Eurogentec, Seraing, Belgium) were transfected (100 nM) 111 
one day prior to initiation of chondrogenic differentiation or at day 6 of differentiation using 112 
HiPerFECT according to manufacturers’ protocol (Qiagen, Hilden, Germany). A custom made DNA 113 
strand containing a start codon and 3xFLAG sequence (derived from p3xFLAG CMV7.1) and the 114 
mSox9 coding sequence (NM_011448.4:376-1899) without start codon was flanked by 5’EcoRI and 115 
3’XbaI restriction sites (GeneCust, Boynes, France). This fragment was cloned directionally into the 116 
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pLVX-EIF1α-IRES puro MCS (Takara, Saint-Germain-en-Laye, France) to generate a pLVX-EIF1α-117 
mSox9-IRES puro transfer plasmid. Lentiviral particles were generated according to manufacturer’s 118 
instructions with the 4th generation VSV-G envelope Lenti-X system (Takara, Saint-Germain-en-Laye, 119 
France). Lentiviral titers were determined by p24 ELISA (enzyme-linked immunosorbent assay; 120 
INNOTEST HIV antigen mAb, Fujirebio, Zwijnaarde, Belgium). Viral transductions were performed 121 
by incubation of 1 ng lentivirus/cell in the presence of 8 µg/mL polybrene (Sigma-Aldrich) for 8 hours, 122 
followed by an overnight incubation with 1.6 µg/mL polybrene.       123 
 124 
RNA isolation  125 
RNA was isolated using TRIzol (Life Technologies), collecting the aqueous phase after centrifugation. 126 
RNA was precipitated with isopropanol (VWR International, Radnor, Pennsylvania, USA) (-80°C) and 127 
pellet by centrifugation. RNA pellets were washed in 80% ethanol (VWR International) and dried. 128 
RNA was dissolved in DNase/RNase-free pure water. RNA quantity and purity were determined 129 
spectrophotometrically (Biodrop, Isogen Life Sciences, Utrecht, The Netherlands). 130 
 131 
Quantitative real time PCR 132 
Total RNA was reverse transcribed into cDNA using standard procedures and random hexamer 133 
priming as previously described (33).   Real-time quantitative PCR (RT-qPCR) was performed using 134 
Mesagreen qPCR master mix plus for SYBR Green (Eurogentec, Liège, Belgium). A CFX96 Real-135 
Time PCR Detection System (Biorad, Hercules, California, United States) was used for amplification: 136 
initial denaturation 95°C for 10 minutes, followed by 40 cycles of amplification (denaturing 15 seconds 137 
at 95°C and annealing 1 minute at 60°C). Validated primer sequences are shown in Supplemental Table 138 
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1. Data were analyzed using the standard curve method, mRNA expression was normalized to a 139 
reference gene and gene expression was calculated as fold change as compared to control conditions 140 
or t=0. 141 
RNA-sequencing and analysis 142 
Isolated RNA was checked for quality and integrity on the Agilent 2100 Bioanalyzer (Santa Clara, 143 
California, USA) via 2100 an Expert Eukaryote Total RNA Nano chip according manufacturer’s 144 
protocol. The mRNA sequencing library was generated using TruSeq mRNA sample preparation kit 145 
(Illumina, Eindhoven, the Netherlands). In short, mRNA was enriched using magnetic beads coated 146 
with poly-dT, followed by fragmentation. The fragmented mRNA enriched samples were subjected to 147 
cDNA synthesis by reverse transcriptase, followed by dA-tailing and ligation of specific double-148 
stranded bar-coded adapters. Next, the library was amplified and following cleanup the sizes of the 149 
libraries were determined on an Agilent 2100 Bioanalyzer via a DNA 1000 chip according 150 
manufacturer’s protocol. Pooled libraries consisting of equal molar samples were sequenced on a high-151 
output 75bp single read on the NextSeq500 (Illumina). For each sample, the number of reads covering 152 
one or more exons of a given transcript were extracted. Triplicates of samples that were treated with 153 
either Scrambled or Sox9 siRNAs, at two different time points, were grouped separately. A transcript 154 
was defined as expressed when all replicates of a group had at least 5 reads extracted within the 155 
transcript's region. The grouped data were then compared to one another. The fold-change difference 156 
and the p-value were calculated using R-package edgeR (34, 35), after which the p-value was corrected 157 
for multiple testing (false discovery rate (FDR)-corrected). Transcripts having an FDR-corrected p-158 
value <0.05, and a fold change of at least 1.5 were considered differentially expressed transcripts. 159 
RNA-seq data have been deposited in the ArrayExpress database at EMBL-EBI 160 
(www.ebi.ac.uk/arrayexpress) under accession number E-MTAB-10333. EnrichR (36) software was 161 
used to display the pathways of interest obtained from the enrichment of down or up-regulated proteins. 162 
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The top three pathways of interest were considered from both Wikipathways and KEGG software 163 
(version 2019, Mouse) based on the combined score of the p-value and the adjusted p-value scores. 164 
Label-free proteomics 165 
At indicated time points, plates were rinsed 3 times with 1% phosphate buffered saline (PBS). A 166 
mixture containing complete Mini Protease Inhibitor Cocktail (Roche, Basel, Switzerland) in 25 mM 167 
ammonium bicarbonate (ABC) buffer (Sigma-Aldrich, Zwijndrecht, The Netherlands) and 6M urea 168 
(GE Healthcare, Eindhoven, The Netherlands) was added to the plates. Cells were collected by scraping 169 
with a rubber policeman and the samples were transferred to Eppendorf tubes. Triplicates were pooled 170 
and sonicated for 10 minutes and centrifuged at 12.000g for 10 min in 4ᵒC. The supernatant containing 171 
proteins was transferred into new tubes and a Bradford assay (Biorad, Lunteren, the Netherlands) was 172 
performed to assess protein concentration. The concentrations were adjusted to 0.2µg/µL in order to 173 
normalize for the following steps. Samples were reduced with 20mM of Dithiothreitol (DTT) (Sigma-174 
Aldrich) for 45 minutes and alkylated with 40 mM of iodoacetamide (IAM; Sigma-Aldrich) for 45 175 
minutes in the dark. The alkylation step was stopped by adding 20 mM of DTT. Samples were then 176 
digested using LysC and trypsin (Promega, Leiden, The Netherlands) added at a ratio of 1:25 177 
(enzyme:protein) and incubated for 2 hours at 37°C in a water bath. Finally, 200 µL of 25 mM ABC 178 
buffer was added to the samples before overnight incubation at 37°C. The digestion was stopped by 179 
adding formic acid (FA; Sigma-Aldrich) and acetonitrile (Biosolve) at a final concentration of 1% and 180 
2%, respectively. 200 ng of each sample were injected in duplicate for liquid-chromatography mass 181 
spectrometry (LC-MSMS) analysis. The separation of the peptides was performed on a Thermo Fisher 182 
Scientific Dionex Ultimate 3000 Rapid Separation ultrahigh-performance liquid-chromatography 183 
(HPLC) system (Thermo Scientific, MA, USA) equipped with an Acclaim PepMap C18 analytical 184 
column (2µm, 75µm*150 mm, 100Å). The samples were first trapped on an online C18 column for 185 
desalting. The peptides were then separated on the analytical column with a 90-minutes linear gradient 186 
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from 5% to 35% acetonitrile/0.1% FA and a flow rate set at 300 nL/min. The HPLC system was 187 
coupled to a high mass resolution Orbitrap MS instrument (Q-Exactive HF, Thermo Scientific, 188 
Waltham, MA). The mass spectrometer was operated in data-dependent acquisition (DDA) mode with 189 
the following settings: Full MS scan of the mass range m/z 350-1,650 at a resolution of 120,000 at m/z 190 
400, followed by tandem mass spectrometry (MS/MS) scans for the fragmentation of the 15 most 191 
intense ions at a resolution of 30,000. The ions already selected for fragmentation were dynamically 192 
excluded for 20s. External calibration of the instrument was performed using a standard calibration 193 
solution for positive ion mode (Thermo Scientific). For protein identification, raw files were processed 194 
within the Proteome Discoverer software version 2.2 (Thermo Scientific) using the search engine 195 
Sequest with the Swiss-Prot database Mus musculus version 2017-10-25 (TaxID 10090). The following 196 
parameters were used for the database search: carbamidomethylation of Cysteine for fixed 197 
modifications; oxidation of Methionine and acetylation of protein N-terminal for variable 198 
modifications; trypsin for enzyme with a maximum of two missed cleavages; y and b for the ion types 199 
with a mass tolerance of 10 ppm and 0.02 Da for the precursors and the fragments, respectively; 200 
minimum and maximum peptide length of 6 and 144, respectively. Normalization of the data was 201 
performed on the total peptide amount. Percolator was used for the decoy database search and the FDR 202 
was fixed at 1% maximum. Finally, a list of 23 commonly detected contaminants were removed 203 
manually (data not shown). For protein quantitation, the Minora Feature Detector node in the 204 
processing step and the Feature Mapper node combined with the Precursor Ions Quantifier node in the 205 
consensus step were used with default settings. The mass spectrometry proteomics data have been 206 
deposited to the ProteomeXchange Consortium via the PRIDE (37) partner repository with the dataset 207 
identifier PXD024715. ANOVA test and principal component analysis (PCA) were performed within 208 
the Proteome Discoverer software. PCA was performed to visualize protein abundance changes 209 
between groups in an unsupervised manner. ANOVA test was used to analyze the statistical 210 
significance of variation observed in protein abundances between the conditions. The proteins were 211 
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considered modulated with a p-value ≤0.05 and a fold change (FC) ≥2. The modulated proteins were 212 
then imported within the EnrichR software (36) to display the top 3 pathways of down or up-regulated 213 
proteins ranked by the combined score. WikiPathways and KEGG were used as databases (version 214 
2019, Mouse). 215 
 216 
Immunoblotting 217 
Cells were lysed in RIPA buffer (150 mM NaCl, 1% NP-40, 0,5% Sodium deoxycholate, 0,1% SDS, 218 
50 mM Tris pH 8.0, 5.0 mM Ethylenediaminetetraacetic acid (EDTA) pH 8.0, 0.5 mM dithiothreitol 219 
(DTT) supplemented with cOmplete Mini Protease Inhibitor Cocktail (Roche) and  PhosSTOP 220 
phosphatase inhibitor (Sigma-Aldrich)). Extracts were sonicated and protein concentrations were 221 
determined with a bicinchoninic acid assay (BCA) assay (Sigma-Aldrich). Proteins were separated by 222 
SDS-PAGE (sodium dodecyl (lauryl) sulfate-polyacrylamide gel electrophoresis) and transferred to 223 
nitrocellulose membranes by electroblotting. Primary antibodies for immunodetection were anti-Sox9 224 
(Abcam, Cambridge, UK; ab3697) and anti-Tubulin (Sigma-Aldrich; T6074). Bound primary anti-225 
bodies were detected using immunoglobulins conjugated with HRP (horseradish peroxidase; 226 
DakoCytomation, Glostrup, Denmark) and visualized by enhanced chemoluminescence (ECL).  ECL 227 
signals were quantified using Image J 1.46f software (Figure 1B). Relative differences in Sox9 levels, 228 
corrected for background and Tubulin levels, were determined as compared to t=0 conditions.   229 
sGAG assay  230 
The sulphated glycosaminoglycan (GAG) content was measured using a modified dimethyl methylene 231 
blue (DMB) assay (38). The absorbance of samples was read at 540 and 595 nm using a 232 
spectrophotometer (Multiskan FC, Life Technologies) and GAG concentrations were calculated using 233 
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a chondroitin sulfate standard curve (Sigma-Aldrich) and corrected for total protein content using a 234 
BCA assay. 235 
 236 
SUnSET assay 237 
Protein translational capacity of ATDC5 cultures (in sextuplicates) was assessed with the SUnSET 238 
assay (39, 40).  5.4 µM puromycin (Sigma-Aldrich) was incubated for 15 minutes in the cell culture 239 
medium, immediately followed by washing in PBS and fixation for 20 minutes with 10% formalin 240 
(VWR, Radnor, Pennsylvania, United States). Permeabilization was performed for 10 minutes with 241 
PBS supplemented with 0.1% Triton X-100. Wells were rinsed with PBS with 0.1% Tween (PBS-T) 242 
and blocked for 1.5 hour with 1% (m/v) skimmed milk powder (ELK, Campina, Zaltbommel, the 243 
Netherlands) in PBS-T, followed by overnight incubation at 4°C with the primary anti-puromycin 244 
antibody 12D10 (Sigma-Aldrich). After washing with PBS-T, wells were incubated for 1 hour at room 245 
temperature with the secondary goat anti-mouse Alexa488 antibody (Life Technologies). The 246 
fluorescent signal intensity was determined using a TriStar2 LB942 (Berthold, Bad Wildbad, Germany) 247 
equipped with excitation filter F485 and emission filter F535. Fluorescent data was normalized to 248 
DNA-content from the same well (41). To this end, wells were washed with HEPES-Buffered Saline 249 
(HBS), followed by 1 hour incubation with 5 µg/mL DAPI (Life Technologies) plus 5 µg/mL 250 
HOECHST 33342 (Life Technologies) in HBS. After subsequent washing steps with HBS, fluorescent 251 
signal intensity was determined using a TriStar2 LB942 (Berthold), using the excitation filter F355 and 252 
emission filter F460. 253 
 254 
 255 
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Polysome fractionation 256 
Polysome fractionation was performed as described previously (42). Three 15 cm plates with ATDC5 257 
cells were used to generate a single sample. At the day of sample collection, cells were differentiated 258 
for 2 hours, then pre-treated for 5 minutes with 100 µg/ml Cycloheximide (Sigma), washed twice in 259 
0.9% NaCl with Cycloheximide and collected by scraping with a rubber policeman in cold 0.9% NaCl. 260 
Pelleted cells were lysed for 10 minutes in 1.8 ml polysome extraction buffer (20 mM Tris-HCl 261 
(pH7.5), 100 mM KCl, 5 mM MgCl2, 0.5% Nonidet P-40, 100 µg/ml Cycloheximide, complete 262 
protease inhibitor cocktail (Roche) and RNasin (Promega, 40U/ml)) on ice. Nuclei and cellular debris 263 
were removed by centrifugation at 12.000x g for 10 minutes at 4⁰C and 9/10th of the total volume was 264 
transferred to fresh tubes and measured spectrophotometrically. Total yield was the same for siCtrl and 265 
siSox9 treated cells. Sucrose gradients (linear 10-50%) were made using the Gradient Master 266 
(BioComp) in ultracentrifuge tubes (Seton, SW41 tubes). Cytoplasmic extracts (250 µg/sample) were 267 
loaded to each gradient in a fixed volume (400 µl). Gradients were run on an ultra-centrifuge (Beckman 268 
L60, Brea, California, USA) at 39.000 rpm for 1.5 hours at 4⁰C with max acceleration and deceleration 269 
9. Samples were fractionated into 24 x 0.5 ml fractions using a Piston Gradient fractionator (BioComp, 270 
Fredericton, Canada) and fraction collector (Gilson FC203B, Middleton, Wisconsin, USA) with 271 
continuous A260 monitoring (Triax FC-1). 272 
 273 
Bicistronic reporter assay 274 
Reporter constructs for the CrPv IGR IRES, the CrPv CCGG IGR IRES mutant, the HCV and the P53 275 
IRES were a kind gift of Dr. S. Thompson (UAB, USA). One day post plating, maxi-prep DNA (0.5 276 
µg/well) and 100 nM siRNA were transfected into 24-wells wells (n=3/group) using Mirus Transit-X2 277 
according to manufacturer’s instructions. The next day differentiation was induced for 24 hours, 278 
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samples were collected by washing cells with 0.9% NaCl and incubation in 100 µl passive lysis buffer 279 
for 15 minutes (Promega). Subsequently, samples were transferred to Eppendorf tubes and centrifuged 280 
for 10 minutes at 12.000x g in a tabletop centrifuge. Next, 50 µl lysate was used for dual luciferase 281 
measurements (Promega) using a Berthold injection system (Reeuwijk, the Netherlands;10 seconds 282 
counting time per cistron). Data is represented as fold change of the ratio Fluc/Rluc in control cells for 283 
each IRES. 284 
Statistics in other than proteomics or transcriptomic analysis 285 
Statistical significance was determined by two-tailed student t-tests using Graphpad PRISM 5.0 (La 286 
Jolla, CA, USA). Error bars in graphs represent mean ± standard error of the mean. Significance for 287 
all tests was set at p≤0.05.  288 
Sox9 influences translational capacity 
 
14 
This is a provisional file, not the final typeset article 
Results 289 
 290 
Early Sox9 peak in ATDC5 chondrogenic differentiation 291 
Induction of Sox9 expression is biphasic during chondrogenic differentiation of progenitor cells in 292 
vitro (30, 31). In the first (2-4) hours after initiation of chondrogenic differentiation of ATDC5 cells 293 
Sox9 expression was transiently induced on mRNA (Figure 1A) and protein level (Figure 1B). Sox9 294 
expression increased a second time around day 7 in differentiation (Figure 1A), in parallel with the 295 
expression of the important Sox9 transcriptional target Col2a1 (21) (Figure 1C) and gain of sulphated 296 
glycosaminoglycan (GAG) content (2, 19) (Figure 1D). The immediate early transient Sox9 expression 297 
peak at 2 hours in differentiation did not correlate with the induction of expression of well-known Sox9 298 
transcriptional targets such as Col2a1. Hence, we questioned what the function of the early Sox9 299 
expression peak (2 hours) was and how it differs from the later Sox9 activity (day 7). We approached 300 
this by performing a loss-of-function experiment and comparing the Sox9-dependent transcriptome 301 
and proteome in an unbiased manner.  302 
Transcriptome and proteome analysis at 2 hours and 7 days in ATDC5 chondrogenic differentiation 303 
under Sox9 knockdown  304 
To target early Sox9 expression, a siRNA for Sox9 or scrambled control siRNA were transfected prior 305 
to initiation of differentiation (t = -1 day) (Figure 2A). At t=0 chondrogenic differentiation was induced 306 
and cells were differentiated for 14 days. We established effective knockdown of Sox9 at t=0 and t=2 307 
hours in differentiation, while at day 5, 7 and 14 in differentiation Sox9 mRNA levels returned to 308 
scrambled siRNA control conditions (Figure 2B; black bars and Figure 2C). In parallel, ATDC5 cells 309 
were differentiated and the siRNA for Sox9 or scrambled siRNA was transfected at day 6 in 310 
differentiation, to specifically target expression of “late” Sox9 induction. Effective knockdown of Sox9 311 
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at day 7 and day 14 was observed at mRNA as well as (Figure 2B; grey bars) at the protein level (Figure 312 
2C). Knockdown of the early Sox9 expression peak resulted in decreased Col2a1 expression, and 313 
increased Col10a1 expression at early time-points. At day 7 and 14 in ATDC5 differentiation, Sox9 314 
siRNA treatment was not effective anymore (Figure 2B; white versus black bars), however, a major 315 
induction of Col2a1 mRNA expression at day 7 and 14 in differentiation was prevented in this 316 
condition (Figure 2D). A similar but opposite effect was seen for Col10a1 expression in the early Sox9 317 
peak knockdown condition (Figure 2E). Knockdown of the “late” Sox9 peak (grey bars) also resulted 318 
in a decreased Col2a1 and increased Col10a1 expression at day 7 and 14 in differentiation, with a 319 
smaller magnitude. These data indicate that the early Sox9 expression peak is paramount for successful 320 
chondrogenic differentiation of ATDC5 cells (see Supplemental Figure 1 for confirmation with 321 
independent Sox9 siRNA). Differential expression of mRNAs and proteins was determined between 322 
the scrambled versus Sox9 siRNA at 2 hours as well as at 7 days in ATDC5 differentiation, to target 323 
the early and late Sox9 expression peaks (Figure 2D).  324 
The extracted RNA was used for RNA sequencing and Principal Component Analysis (PCA) of the 325 
transcriptome confirmed that samples from the 4 groups separated (Supplementary Figure 2). 326 
Noteworthy, the separation between the scrambled siRNA and Sox9 siRNA conditions was evident at 327 
2 hours, while separation between the scrambled siRNA and Sox9 siRNA conditions at 7 days was less 328 
clear. At 2 hours in ATDC5 chondrogenic differentiation, knockdown of Sox9 led to the differential 329 
expression of 2422 genes, with 1235 upregulated genes and 1187 downregulated genes (Figure 3A/B). 330 
At 7 days in differentiation 493 genes were differentially expressed (203 up and 290 down) due to 331 
knockdown of Sox9. From these differentially expressed genes, 203 genes were upregulated (only 15 332 
overlapped with the 2 hour time point) and 290 genes were downregulated (49 genes overlapped with 333 
the 2 hours condition) (Figure 3A/B). All genes that were differentially expressed (FC≥2; p<0.05) at 2 334 
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hours and at 7 days in ATDC5 chondrogenic differentiation following Sox9 knockdown, are shown in 335 
Supplementary Tables 2 and 3, respectively.  336 
Proteins from control conditions and Sox9 knockdown conditions at 2 hours and 7 days in ATDC5 337 
differentiation were quantified using a label-free proteomics approach. PCA plotting confirmed that 338 
control samples at 2 hours clearly separated from the Sox9 knockdown samples at 2 hours in ATDC5 339 
differentiation. Separation between control and Sox9 knockdown conditions was also confirmed at 7 340 
days in chondrogenic differentiation. However, and in concert with the PCA plot of the RNA 341 
sequencing data (Supplementary Figure 2), the separation between control and Sox9 knockdown 342 
conditions appeared to be most obvious at 2 hours in differentiation (Supplementary Figure 3A). At 2 343 
hours in differentiation, knockdown of Sox9 caused the differential expression of 90 proteins (29 up 344 
and 61 down)(Figure 3C/D and Supplemental Figure 3B). At 7 days in differentiation, the knockdown 345 
of Sox9 induced differential expression of 19 proteins (9 up and 10 down). There was no overlap 346 
between the Sox9-dependent differentially expressed proteins at 2 hours or at 7 days in differentiation 347 
(Figure 3C/D and Supplemental Figure 3B). The proteins that were differentially expressed (FC≥2; 348 
p<0.05) at 2 hours and at 7 days in ATDC5 chondrogenic differentiation following Sox9 knockdown, 349 
are shown in Supplementary Tables 4 and 5, respectively. 350 
These data indicate that at 2 hours in chondrogenic differentiation the knockdown of Sox9 induced 351 
different changes in the ATDC5 transcriptome and proteome when compared to knockdown of Sox9 352 
at 7 days in differentiation. In addition, the consequences of Sox9 siRNA treatment appears to be 353 
stronger at 2 hours than at 7 days of differentiation, as indicated by larger separation in the PCA plots 354 
and larger number of differentially expressed genes and proteins. The role of the immediate early Sox9 355 
expression was further investigated by comparing the Sox9-dependent differentially expressed mRNAs 356 
and proteins at 2 hours in differentiation. Four overlapping mRNAs and proteins are upregulated in the 357 
early Sox9 knockdown condition (Rps30/Fau, Avan, Eefsec, Rpl38; Figure 3E and 3F, Supplementary 358 
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Table 6) and 3 overlapping mRNAs and proteins downregulated in the early Sox9 knockdown 359 
condition (Ube2d3, Dclk1, Svil; Supplementary Table 6). Except for Rpl38, these overlapping targets 360 
are unique for the 2 hour in differentiation time point.  The relative low number of overlapping genes 361 
and proteins (Figure 3E and F) might be explained by the different control of expression regulation at 362 
different levels for RNA and protein (43) and the notion that not all mRNAs are instantaneously 363 
translated into protein. Overlapping targets might be involved in a biological process which reacts 364 
fastest in a way that is visible in both RNA and protein expression. 365 
 366 
Immediate early Sox9 expression is involved in ribosomal protein expression 367 
To determine which prominent pathways link to the Sox9-dependent differential transcriptome and 368 
proteome at 2 hours in differentiation, we performed pathway analyses. Two independent Pathway 369 
analyses revealed that “Cytoplasmic Ribosomal Proteins” and “Ribosome” pathways were in the top 370 
three of identified enriched pathways (Figure 4). This strong overrepresentation of the “Cytoplasmic 371 
Ribosomal Proteins” and “Ribosome” pathways was not obvious in the Sox9-dependent differential 372 
transcriptome and proteome at day 7 in differentiation (Supplementary Table 7). Further analysis 373 
revealed the differential expression of 29 ribosomal protein encoding genes from the large (60S) 374 
ribosomal subunit (Rpls) and 10 ribosomal proteins from the small (40S) ribosomal subunit (Rpss) in 375 
the Sox9 knockdown condition at 2 hours in ATDC5 chondrogenic differentiation (Figure 5A and 376 
Supplementary Table 2). In addition, the 2 hours proteomics datasets demonstrated the differential 377 
expression of 5 ribosomal Rpl and Rps proteins (Figure 5A and Supplementary Table 4). Notably, the 378 
4 overlapping mRNAs and proteins (Rps30/Fau, Avan, Eefsec, Rpl38) that were upregulated in the 379 
Sox9 knockdown condition at 2 hours in ATDC5 chondrogenic differentiation (Figure 3E and Figure 380 
5B, Supplementary Figure 4A) are all linked to protein translation and represent either ribosomal 381 
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protein subunits or factors with a known function in ribosome biogenesis. Additional factors involved 382 
in ribosome biogenesis, but only differentially expressed in either the 2 hours transcriptomics or 383 
proteomics datasets were SBDS, Nop10 and Brix1 (Figure 5B. Supplementary Tables 2 and 3). Where 384 
expression of Sox9 was significantly increased at two hours in ATDC5 differentiation, expression of 385 
Rpl38, Rps30/Fau, Nop10 and SBDS was significantly decreased compared to t0 (Supplementary 386 
Figure 4C). Since ribosomes do not only consist of proteins, but depend on structural and catalytically 387 
active ribosomal RNAs (rRNAs), we investigated whether rRNA levels were affected by the Sox9 388 
knockdown at 2 hours in differentiation in ATDC5. Expression of 18S rRNA, 28S rRNA and 5.8S 389 
rRNA was not significantly different between the conditions (Figure 5C) (see Supplemental Figure 4B 390 
for confirmation with independent Sox9 siRNA). Together, these data indicate that the Sox9 expression 391 
during early ATDC5 chondrogenic differentiation is involved in expression of ribosomal proteins and 392 
proteins involved in ribosome biogenesis.  393 
Early Sox9 expression regulates protein translation capacity and ribosome translation modus 394 
Since we identified the differential expression of ribosomal protein subunits and ribosome biogenesis 395 
factors, combined with unaltered rRNA expression levels, we hypothesized that ribosomes of early 396 
Sox9 knockdown ATDC5 cells are functionally distinct. To address this, we measured total 397 
translational capacity, performed polysome fractionation and evaluated ribosome translation modus in 398 
Sox9 knockdown and control ATDC5 cells. Following the knockdown of immediate early Sox9 399 
expression a reduction of the total protein translational capacity was observed at 2 hours in 400 
chondrogenic differentiation (Figure 6A). The abrogation of early Sox9 expression also caused a 401 
reduction of total protein translational capacity at day 7 in differentiation (while Sox9 levels normalized 402 
at 7 days following the early knockdown (Figure 2B)). This impact on translation capacity was lost at 403 
day 14 in differentiation (Figure 6A). In contrast, late knockdown of Sox9 expression did not affect 404 
ATDC5 translational capacity at 7 days in chondrogenic differentiation. This is consistent with 405 
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transcriptome and proteome data. To assess if Sox9 knock-down had a specific effect on polysomal 406 
distribution of ribosomes, we performed sucrose density gradient separation of ribosomal subunits. 407 
Knockdown of the immediate early Sox9 expression resulted in an overall lower abundance of 408 
ribosomal subunits, which is in agreement with reduced translational activity (Figure 6B). In addition 409 
to total ribosome translation capacity (Figure 6A), the modus of translation is also subject to regulation. 410 
Thus, we evaluated the activity of IRES (internal ribosome entry site)- over cap-mediated protein 411 
translation using well-characterized bicistronic reporter constructs (CrPv IGR, HCV and P53 IRES) 412 
(44-46). We observed a 1.5-fold induction of the ITAF (IRES trans-acting factor) independent CrPv 413 
IGR IRES activity and 5-fold down regulation of both the HCV and P53 IRES activity in Sox9 414 
knockdown ATDC5 cells compared to controls (Figure 6C, and Supplementary Figure 5). We next 415 
investigated whether overexpression of Sox9 levels during early ATDC5 differentiation may have a 416 
reciprocal effect on the translation capacity as opposed to the Sox9 knockdown conditions. 417 
Overexpression of Sox9 was confirmed (Figure 7A) and the mRNA expression of the Sox9 418 
transcriptional target Col2a1 was significantly induced by Sox9 overexpression (Figure 7A). The 419 
overexpression of Sox9 resulted in a significant increase in translational capacity at 2 hours in ATDC5 420 
differentiation (Figure 7B). This increase in translational capacity in the Sox9 overexpression condition 421 
was not accompanied by an increase in expression of rRNAs (Figure 7C). Contrary to the knockdown 422 
of Sox9 (Figure 5B), expression of ribosomal protein subunits Rpl38 and Rps30/Fau was significantly 423 
downregulated when Sox9 was overexpressed (Figure 7D). This was also the case for ribosome 424 
biogenesis factors Nop10 and SBDS (Figure 7D).  425 
Taken together, knockdown of early Sox9 expression during ATDC5 chondrogenic differentiation 426 
reduced protein translational activity over a seven-day time period, which was reflected by a general 427 
reduction of A260 signal in a polysome fractionation experiment at 2 hours in differentiation. This was 428 
associated with a differential effect on ribosome translation modus during the first day of 429 
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differentiation. Sox9 overexpression during early ATDC5 differentiation was able to induce reciprocal 430 
effects of the Sox9 knockdown on total protein translation.   431 
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Discussion  432 
 433 
Early chondrogenic lineage commitment during mesenchymal condensation is driven by Sox9 (15, 47, 434 
48). Following lineage commitment, Sox9 is a key regulator of cartilage ECM synthesis, by driving 435 
expression of key ECM molecules such as Acan, Col2a1 and others (15, 19-26). Sox9 also safeguards 436 
maintenance of articular cartilage homeostasis by influencing chondrocyte Nkx3-2 levels, a 437 
transcriptional repressor of chondrocyte hypertrophy (49, 50). This dual action of Sox9 is recapitulated 438 
in in vitro models of chondrogenic differentiation, as we have previously reported on bi-phasic 439 
expression dynamics of Sox9 in ATDC5 and bone marrow derived stem cells (BMSC) chondrogenic 440 
differentiation (30, 31). In this earlier work we demonstrated that early (hours) transient induction of 441 
Sox9 expression driven by NFB/p65 or Egr1 in ATDC5 chondrogenic differentiation is a prerequisite 442 
for late-stage (days) expression of cartilage ECM genes. As a key transcription factor for cartilage, the 443 
vast majority of investigations on the downstream functions of Sox9 have mainly focussed on its role 444 
in the transcriptional regulation of cartilage ECM genes (15, 19-26). In addition, a function in 445 
epigenetic reprogramming has been suggested for early Sox9 (31) , as well as a role for Sox9 in 446 
activating super-enhancers in chondrocytic cells (51). However, its downstream cell biological 447 
consequences during early chondrogenic differentiation are incompletely understood. The present 448 
study demonstrates that Sox9 expression during the very early phase of ATDC5 chondrogenic 449 
differentiation regulates the expression of ribosomal protein subunits, as well as proteins that are 450 
involved in ribosome biogenesis that together modulate ribosome activity and translation modus. These 451 
data, for the first time, connect the Sox9 transcription factor to regulation of protein translation during 452 
chondrogenic differentiation. 453 
Ribosomopathies are severe genetic diseases caused by mutations in genes involved in ribosome 454 
biogenesis and -function and are, amongst others, associated with developmentally-related skeletal 455 
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malformations, caused by impairment of chondrogenic development of the growth plates (52, 53). This 456 
indicates that chondrogenic differentiation is particularly susceptible to disturbances in ribosome 457 
protein translation activity. Indeed, during chondrogenesis, a large amount of cartilage ECM is 458 
produced by the developing growth plate and disturbances in ribosome activity are likely to impair 459 
ECM synthesis, with consequences for the development of skeletal elements. It should however be 460 
noted that the link between Sox9 and chondrocyte translation activity in the current work was 461 
particularly present during early rather than late differentiation. This is highlighted by the deregulated 462 
expression of ribosomal subunits following Sox9 knockdown in early ATDC5 chondrogenic 463 
differentiation (Figure 4 and 5). In addition, the knockdown of Sox9 specifically impacted total protein 464 
translation throughout differentiation upon early knockdown, while not having an effect on protein 465 
translation when knocked-down during later in chondrogenic differentiation (Figure 6). The link 466 
between early Sox9 and chondrocyte protein translation suggests that protein translation is likely to be 467 
paced through Sox9 during early chondrogenic differentiation. However, it remains to be determined 468 
how early Sox9 is specifically able to influence chondrocyte translational capacity. Our present data 469 
suggest that expression of ribosomal protein subunits, ribosome biogenesis factors and ancillary 470 
ribosomal factors (such as IRES trans-acting factors (ITAFs)) depends on Sox9 during early 471 
chondrogenic differentiation, with downstream consequences for translation in the later differentiation 472 
program. Since we found these ribosomal genes and proteins differentially expressed after Sox9 473 
knockdown, we studied the supplementary data of previously published Sox9 ChIP-seq and Sox9-/- 474 
mouse studies (48, 51). In supplementary data of a Sox9 ChIP-seq study we found 24 Rps and Rpl 475 
genes that were enriched in Sox9 occupancy and 14 with Sox6 occupancy of which 10 overlapped (51). 476 
Notably, this included Rpl38, which we found to be differentially expressed at the mRNA and protein 477 
level in our present Sox9 knockdown condition.  478 
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Aside from ribosome core components, we identified Sox9-dependent differential expression of 479 
several factors regulating the mode of protein translation. The rate-limiting step of cap-mediated 480 
translation is eukaryotic initiation factor 4 (54). Interestingly, EIF4BP2 was downregulated at the 481 
protein level at 2 hours of differentiation in Sox9 knockdown cells. EIF4 binding proteins were shown 482 
to regulate cell proliferation, but not cell size (55). Unexpectedly, we found strong differences in IRES 483 
activity upon early Sox9 knockdown after 24 hours of differentiation. Of note, the CrPv IGR IRES (a 484 
type IV IRES (56)) does not require ITAFs and is able to recruit the ribosome directly for translation 485 
(57). The activity of this IRES was increased and might be regulated by specific Rps/Rpls that 486 
transiently interact with the core ribosome components. The HCV (a type III IRES) and P53 IRES do 487 
require additional ITAF co-factors (58). Based on the increased expression of the ITAF Rpl38 (59), it 488 
is tempting to speculate that other ITAFs that facilitate HCV/P53 IRES translation are down regulated 489 
and may contribute to alternative use of ribosome translation modus. Rpl10a, Rpl11, Rpl38 and Pdcd4 490 
were shown to regulate IRES-mediated translation (58). Rpl10a is known to activate the IGF2, APP, 491 
Chmp2A and Bcl-2 IRESs. Gain- and loss-of-function studies in Drosophila showed that Rpl10a 492 
regulates insulin signaling (60). Moreover, Rpl10a was found to be preferentially translated by a sub 493 
pool of ribosomes in embryonic stem cells that required ribosome-associated Rpl10a (61). Insulin and 494 
insulin-like growth factor I (IGF1) signaling are crucial for ATDC5 differentiation (32). Rpl11 induced 495 
the BAG1, CSDE1 and LamB1 IRESs, while Rpl38 activated a Hox gene IRES (59, 62). Upregulation 496 
of Rpl11 led to stabilization of P53 and reduced proliferation of breast cancer cell-lines (63). In 497 
contrast, we found a reduction in P53 IRES activity. Of note, P53 and ribosome biogenesis were 498 
recently coupled through SBDS (Ribosome Maturation Factor)(63). In our dataset, SBDS was down 499 
regulated at the protein level at 2 hours in differentiation in Sox9 siRNA treated cells, which matches 500 
the observed reduction in ribosomes and/or ribosome activity. Pdcd4 activated or inhibited the P53, 501 
INR, IGF1R, BcL-XL and XIAP IRESs (58). The IGF1R IRES might again be relevant for the ATDC5 502 
differentiation model. Finally, Rpl38 was the only ITAF that was found to be upregulated at both the 503 
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mRNA and protein level. It was found to control HOX gene translation during murine embryonic 504 
development (59) and knockout led to ectopic mineralization in certain soft tissues (64). 505 
We identified multiple connections between immediate early Sox9 expression during ATDC5 506 
chondrogenic differentiation and downstream consequences for expression of ribosomal protein 507 
subunits, ribosome biogenesis factors and ITAFs. The connection between Sox9 expression and protein 508 
translation appears to be centered in early chondrogenic differentiation, with consequences for protein 509 
translation in later stage of chondrogenic differentiation. This suggests a role for early Sox9 in the 510 
priming of progenitor cells in the chondrogenic differentiation program for cartilaginous ECM 511 
production later in differentiation. This provides a new level of understanding how Sox9 controls the 512 
fate of chondrogenic differentiation at the level of protein synthesis. In this respect it is tempting to 513 
speculate on the classification of campomelic dysplasia (OMIM #114290) (65), as links between Sox9 514 
and genes involved in ribosomopathies (52, 66) were identified in the present work (SBDS, Rpl11, 515 
Rps26). In conclusion, we collected essential new data on the regulation by Sox9 during early 516 
chondrogenic differentiation, uncovering an unanticipated role of Sox9 in ribosome biogenesis and 517 
protein translational capacity.   518 
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In our previous research, we demonstrated that chondrogenic differentiation of progenitor cells is 526 
driven by a sharply defined bi-phasic expression of Sox9: an immediate early and a late phase 527 
expression. The late phase expression of Sox9 is associated with cartilage extracellular matrix 528 
formation, while the function of the early Sox9 induction itself remained elusive. In this study we 529 
aimed to determine what biological processes are driven by Sox9 during the early phase of 530 
chondrogenic differentiation. We identified an essential new function for Sox9 during early 531 
chondrogenic differentiation. A role for Sox9 in regulation of ribosome amount, activity and 532 
composition was found and may be crucial in preparation for the demanding proliferative phase and 533 
subsequent cartilage extracellular matrix-production of chondroprogenitors in the growth plate in vivo. 534 
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Figure legends 768 
 769 
Figure 1: Sox9 expression has a bi-phasic peak expression during chondrogenic differentiation of 770 
ATDC5 cells 771 
A: Sox9 mRNA expression showed bi-phasic peak pattern during ATDC5 differentiation (h=hours, 772 
d=days) as measured by RT-qPCR (30, 31). Results were normalized to β-Actin mRNA expression 773 
and presented relative to t=0. B: Sox9 protein expression peak during early ATDC5 differentiation as 774 
measured by immunoblotting. α‐Tubulin was used as loading control. Molecular weight markers (in 775 
kDa) are shown on the left and relative quantifications are depicted on top of immunoblot. C: In similar 776 
samples from (A), Col2a1 mRNA expression was measured during ATDC5 differentiation by RT-777 
qPCR and showed an increase in expression from day 6 onwards. D: GAG content (by Alcian Blue 778 
staining and corrected for total protein expression) was determined during ATDC5 differentiation. 779 
Experiments were performed in triplicate, bars represent mean±SEM. ns= not significant, *=p<0.05, 780 
**=p<0.01, ***=p<0.0001.  781 
 782 
Figure 2: Elucidating the function of early Sox9 expression by transcriptome and proteome analyses  783 
A: Schematic representation of experimental set-up for Sox9 knockdown experiment. Specific Sox9 784 
RNAi (100 nM) or scrambled control RNAi (100 nM) were transiently transfected “early” at t=-1d or 785 
“late” t=6d. ATDC5 cells were differentiated from day 0 onwards and harvested for transcriptome and 786 
proteome analysis at at t=0, 2h, 5d, 7d, 14d. B: Sox9 mRNA expression during ATDC5 differentiation 787 
in Control and Sox9 RNAi conditions (h=hours, d=days) as measured by RT-qPCR. Results were 788 
normalized to β-Actin RNA expression and presented relative to t=0. Bars represent mean±SEM. ns= 789 
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not significant, *=p<0.05, **=p<0.01, p=<0.0001. C: Sox9 protein expression at t=2h (for “early 790 
knockdown condition) and t=7d (for “late” knockdown conditions) time point in Control and Sox9 791 
RNAi conditions as measured by immunoblotting. α‐Tubulin was used as loading control. Molecular 792 
weight markers (in kd) are shown on the left. D: Col2a1 mRNA expression in similar samples from 793 
(B). E: Col10a1 mRNA expression in similar samples from (B). F: Schematic representation of time 794 
points and comparisons for transcriptomics and proteomics analysis.  795 
 796 
Figure 3: Changes in transcriptome and proteome after Sox9 knockdown 797 
 798 
A:  Venn diagram (67) showing the numbers of genes whose expression was significantly upregulated 799 
upon Sox9 knockdown at 2 hours versus 7 day condition. B: Venn diagram showing the numbers of 800 
genes whose expression was significantly downregulated upon Sox9 knockdown at 2 hours versus 7 801 
day condition. C: Venn diagram showing the numbers of proteins whose expression was significantly 802 
upregulated upon Sox9 knockdown at 2 hours versus 7 day condition. D: Venn diagram showing the 803 
numbers of proteins whose expression was significantly downregulated upon Sox9 knockdown at 2 804 
hours versus 7 day condition. E: Venn diagram showing the upregulated genes versus proteins at 2 805 
hours in differentiation. F: Venn diagram showing the downregulated genes versus proteins at 2 hours 806 
in differentiation. 807 
 808 
Figure 4: Early Sox9 expression is involved in ribosomal pathways 809 
Top 3 identified enriched pathways from WikiPathway 2019 and KEGG2019 pathway analysis in 810 
control RNAi compared to Sox9 RNAi at 2 hours condition in ATDC5 differentiation for transcriptome 811 
and proteome data sets.  812 
 813 
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Figure 5: Early Sox9 regulates ribosomal protein expression 814 
A: Schematic representation of significantly differentially expressed ribosomal proteins from 815 
transcriptome and proteome datasets based on Wikipathways (68): WP163 using PathVisio 3 (69).  B: 816 
Rpl38, Rps30/Fau, Nop10 and SBDS expression at 2 hours in ATDC5 differentiation in Control and 817 
Sox9 RNAi conditions as measured by RT-qPCR. Results were normalized to β-Actin RNA expression 818 
and presented relative to t=0. C: In similar samples from B; 18S rRNA, 28S rRNA and 5.8S rRNA 819 
expression. Bars represent mean±SEM. ns= not significant, *=p<0.05, **=p<0.01, ***=p<0.0001. 820 
 821 
Figure 6: Knockdown of early Sox9 expression leads to a reduced translational capacity, lower amount 822 
of ribosomes and alters ribosome modus  823 
A: Total protein translation measurements based on puromycin incorporation was normalized to total 824 
DNA content per well (Mean±SEM, n=6/group) at indicated time points. B: Polysome fractionation of 825 
control and Sox9 knock-down cells (Mean only, n=3/group) after 2 hours of differentiation. C: 826 
Ribosome modus was assessed for the CrPv IGR CCGG mutant IRES, the intact CrPv IGR IRES, the 827 
HCV IRES and the P53 IRES after 24 hours of differentiation. Bars represent mean±SEM. ns= not 828 
significant, *=p<0.05, **=p<0.01, p=<0.0001. 829 
 830 
Figure 7: Overexpression of early Sox9 leads to an increased translational capacity  831 
A: Sox9 mRNA expression at 2 hours in ATDC5 differentiation in Control and Sox9 overexpression 832 
(OE) conditions as measured by RT-qPCR. Results were normalized to β-Actin RNA expression and 833 
presented relative to t=0.  B: Total protein translation measurements based on puromycin incorporation 834 
was normalized to total DNA content per well (Mean±SEM, n=6/group) at indicated time points. C: 835 
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In similar samples from A; 18S rRNA, 28S rRNA and 5.8S rRNA expression at 2 hours in ATDC5 836 
differentiation in Control and Sox9 overexpression conditions. D: In similar samples from A; Rpl38, 837 
Rps30/Fau, Nop10 and SBDS expression at 2 hours in ATDC5 differentiation in Control and Sox9 838 
overexpression conditions. Bars represent mean±SEM. ns= not significant, *=p<0.05, **=p<0.01, 839 
p=<0.0001. 840 
